Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Cladribine + Cytarabine + Uproleselan|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Cladribine||Leustatin||2-CdA||Leustatin (cladribine) is a purine analog that is incorporated into DNA, resulting in DNA single strand breaks and apoptosis (NCI Drug Dictionary).|
|Cytarabine||Cytosar-U||Ara-C||Cytosar-U (cytarabine) is a cytidine analog that, when incorporated into DNA, inhibits DNA synthesis and repair (PMID: 32524309).|
|Uproleselan||GMI-1271||Uproleselan (GMI-1271) is a small molecule that binds to E-selectin and prevents E-selectin mediated cell-cell interaction, therefore, modulating inflammation and tumor progression (PMID: 26834953).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04848974||Phase Ib/II||Cladribine + Cytarabine + Uproleselan||Uproleselan, Cladribine, and Low Dose Cytarabine for the Treatment of Patients With Treated Secondary Acute Myeloid Leukemia||Recruiting||USA||0|